Hypermarcas (HYPMY) Set to Release Quarterly Earnings on Wednesday

Key Points

• Hypermarcas is expected to report quarterly results after Wednesday’s market close, with analysts forecasting $0.14 earnings per share and $450.75 million in revenue.
• In its previous quarter, the company earned $0.14 per share, topping the $0.13 consensus estimate. Analysts expect full-year EPS of $0.50 and next-year EPS of $0.58.
• The stock was down 3.5%; analyst coverage remains positive overall, with a consensus Buy rating.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) is projected to post its results after the market closes on Wednesday, November 11th. Analysts expect the company to post earnings of $0.14 per share and revenue of $450.75 million for the quarter.

Hypermarcas (OTCMKTS:HYPMY - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, beating the consensus estimate of $0.13 by $0.01. Hypermarcas had a return on equity of 12.68% and a net margin of 19.77%. On average, analysts expect Hypermarcas to post $0.50 EPS for the current fiscal year and $0.58 EPS for the next fiscal year.

Hypermarcas Trading Down 3.5%

HYPMY stock opened at $3.83 on Wednesday. The company has a market cap of $2.70 billion, a P/E ratio of 7.94 and a beta of 0.78. Hypermarcas has a twelve month low of $3.39 and a twelve month high of $5.77. The company has a quick ratio of 1.26, a current ratio of 1.86 and a debt-to-equity ratio of 0.50. The business has a fifty day moving average of $4.65 and a 200-day moving average of $4.43.

Analyst Ratings Changes

Separately, Jefferies Financial Group upgraded Hypermarcas to a "strong-buy" rating in a research report on Monday, July 20th. One equities research analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Buy".

About Hypermarcas

Hypermarcas SA was a Brazilian consumer-health and pharmaceutical company that later changed its corporate name to Hypera SA The company was established as a diversified consumer-products business and, over time, shifted its focus toward pharmaceuticals and healthcare products.

Hypera develops, manufactures and markets prescription medicines, generic and branded-generic drugs, over-the-counter products, vitamins and nutritional supplements. Its portfolio has included well-known Brazilian consumer-health brands such as Neosaldina, Doril, Engov, Benegrip and Addera D3, serving categories including pain relief, cold and flu treatment, digestive health and vitamins.

The company's principal market is Brazil, where its products are distributed through pharmacies, retailers and other healthcare channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.